DOCSLIB.ORG

A Systematic Review and Meta-Analysis of Oxaceprol in The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Systematic Review and Meta-Analysis of Oxaceprol in The Pharmacological Reports 71 (2019) 374–383 Contents lists available at ScienceDirect Pharmacological Reports journal homepage: www.elsevier.com/locate/pharep Review article A systematic review and meta-analysis of oxaceprol in the management of osteoarthritis: An evidence from randomized parallel-group controlled trials Sharanbasappa Durg*, Melita Lobo, Lakshmi Venkatachalam, Guruprasad Rao, Jignesh Bhate Real World Evidence, Molecular Connections (P) Ltd., Basavanagudi, Bengaluru, India A R T I C L E I N F O A B S T R A C T Article history: Oxaceprol, a derivative of L-proline, is an established drug for managing osteoarthritis (OA) with better Received 6 September 2018 safety profile than non-steroidal anti-inflammatory drugs (NSAIDs). This systematic review and meta- Received in revised form 10 November 2018 analysis, following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Accepted 21 December 2018 guidelines, evaluated the efficacy, safety and tolerability of oxaceprol in OA. Electronic databases for Available online 26 December 2018 published and grey (unpublished) literature were searched to identify parallel-group randomized controlled trials (RCTs) evaluating the impact of oxaceprol in patients with OA. Risk of bias was assessed Keywords: using the Cochrane collaboration's tool. A total of seven parallel-group RCTs involving 1087 participants Oxaceprol Osteoarthritis were included in the systematic review. Meta-analysis, in Review Manager, demonstrated numerically greater/significant improvements compared to active control [diclofenac/ibuprofen]/placebo in pain and Systematic review Meta-analysis function of joint; similar improvement vs. active control in global treatment efficacy; no difference/ Safety significant difference vs. active control/placebo in NSAIDs as rescue medication. Treatment with oxaceprol showed numerically less adverse events (AEs) than active control (diclofenac: risk ratio [RR], 0.71; 95% confidence interval [CI], 0.45 to 1.11; p = 0.14: ibuprofen: RR, 0.73; 95% CI, 0.30 to 1.78; p = 0.49) and significantly fewer AEs compared to placebo (RR, 0.76; 95% CI, 0.63 to 0.92; p = 0.004). Given the nature of small-to-moderate sample size and short duration of eligible studies, the available clinical evidence of oxaceprol in the management of OA is modest – though looks promising. New and better RCTs with larger sample size and longer follow-up are warranted to strengthen the use of oxaceprol in clinical setting for managing OA. © 2018 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved. Contents Introduction . 375 Methods . 375 Literature search . 375 Inclusion and exclusion criteria . 376 Data extraction and quality (risk of bias) assessment . 376 Statistical analysis . 376 Results . 376 Study selection and characteristics of included studies . 376 Quality (risk of bias) assessment . 377 Pain and function of joint . 377 Lequesne joint function index . 377 Joint mobility . 377 * Corresponding author. E-mail address: [email protected] (S. Durg). https://doi.org/10.1016/j.pharep.2018.12.010 1734-1140/© 2018 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved. S. Durg et al. / Pharmacological Reports 71 (2019) 374–383 375 Pain at rest and weight-bearing pain . 377 Pain-free walking time/pain-free duration . 378 Pain on movement (active and passive) . 378 Other pain variables . 379 Global treatment efficacy (Efficacy judgment by investigators/physicians and patients) . 379 NSAIDs as rescue medication . 379 Safety and tolerability . 380 Discussion . 380 Strengths . 381 Limitations . 381 Conclusion . 381 Conflict of interest . 381 Acknowledgments . 381 References . 381 Introduction activity, has been widely used in managing OA since several years [25]; Table S1 lists various proprietary (trade) products containing Osteoarthritis (OA), a chronic and progressive degenerative oxaceprol with their respectivemanufacturerandcountry.Oxaceprol joint disease or degenerative arthritis, is the most common chronic mainly acts by inhibiting leukocyte adhesion and migration [25,26]; condition of the joints, affecting most often the knees, hips, and however, NSAIDs act by peripheral inhibition of prostaglandin (PG) hands [1,2]. The prevalence and incidence of OA vary depending synthesis and a variety of other peripheral and central mechanisms on: non-modifiable systematic risk factors, such as age, sex, [27]. This unique mechanism of oxaceprol in ameliorating OA pain genetics, and ethnicity; modifiable systematic risk factors includ- and stiffness demonstrates better GI safety, in particular when ing obesity, diet, and bone metabolism; modifiable local risk compared with NSAIDs [25,28–32]. A recent experimental compara- factors like muscle strength, physical activity/occupation, joint tive study evaluated the therapeutic efficacy of intra-articular injury, joint alignment, and leg length inequality [3]. The latest injection of oxaceprol and corticosteroid. The study reported World Health Organization (WHO) data report OA as one of the ten improvement of articular cartilage with oxaceprol treatment in most disabling diseases in developed countries. Globally, about monosodium iodoacetate-induced OA in experimental rabbits. 9.6% and 18% of men and women, respectively, aged older than 60 Oxaceprol, after 28 days of treatment, was therapeutically equivalent years are diagnosed with symptomatic OA. Around 25% of the OA to corticosteroid in reducing knee swelling and pain (analgesic population is unable to perform their major daily activities of life, activity) – measured via wire walking and hot plate methods. and 80% have restricted movements [1], resulting in increased risk Histological assessment reported that oxaceprol supplementation for all-cause mortality [4]. It is estimated that, by 2050, worldwide protected articular cartilages from degenerative changes in OA. no less than 130 million people will be impacted from OA [5]. Further, comparable improvement in bone and cellular matrixes Management of OA is primarily categorized as: non-pharma- was observed with oxaceprol and corticosteroid treatment [33]. cologic, pharmacologic, complementary and alternative, and Building on the above facts, the present study aimed to surgical [6]. Currently, the management of OA is merely palliative systematically assess the clinical efficacy, safety and tolerability of and principally focused on the alleviation of pain and symptoms oxaceprol in the managementof OA.The authors, in addition, sought to [7]. In general, non-pharmacologic management recommends diet draw a conclusion whether oxaceprol finds its place in managing OA. and encourages regular exercise to lose weight in case of obesity or overweight; one of the most important modifiable systematic risk Methods factors [3,6,7]. Complementary and alternative approach is widely recommended which involves acupuncture, heat and cold pad, Literature search balneotherapy, orthosis, glucosamine, chondroitin, capsaicin cream, S-adenosylmethionine; however, clinical practice data This systematic review and meta-analysis followed the show limited use of several of these in managing OA [6–8]. The Preferred Reporting Items for Systematic reviews and Meta- surgical interventions are arthroscopy, joint lavage, and total joint Analyses (PRISMA) guidelines [34]. Electronic literature search replacement; these options are reserved for those who do not from the earliest available date to December 2017 was performed show any improvement with non-pharmacologic, complementary in PubMed/MEDLINE, Scopus, EMBASE, Web of Science, and the and alternative, as well pharmacologic approach [6,7]. Pharmaco- Cochrane Central Register of Controlled Trials (CENTRAL) data- logically, non-steroidal anti-inflammatory drugs (NSAIDs) are the bases using the MeSH terms/Emtree (for EMBASE)/keywords cornerstone in the management of OA pain [9,10]. The drug related to oxaceprol and OA: “N-acetyl-4-hydroxyproline” OR “N- utilization studies, in different parts of the world, reported that acetylhydroxyproline” OR “N-acetyl cis-4-hydroxy-L-proline” OR NSAIDs are most widely prescribed in managing OA pain [11–15]. “oxaceprol” AND “osteoarthritis” OR “osteoarthritis, knee” OR The recent study by da Costa and team assessed the efficacy of “osteoarthritides, knee” OR “gonarthrosis” OR “osteoarthritis, hip” NSAIDs for treating knee and hip OA pain and reported that OR “osteoarthritides, hip” OR “coxarthrosis.” Grey (unpublished) paracetamol is clinically ineffective to be recommended for the literature was searched in the following trial registries: US National symptomatic management of OA, irrespective of dose. Further, the Institutes of Health (NIH; https://clinicaltrials.gov/) and the WHO study noted sound evidence on diclofenac (150 mg/day) use for International Clinical Trials Registry Platform (ICTRP; http://apps. improving pain and physical function [10]. However, the accumu- who.int/trialsearch/). The US Food and Drug Administration lated clinical evidence generally recommends to consider the (USFDA) website (https://www.fda.gov/) was also searched for gastrointestinal (GI), cardiovascular (CV), and other safety profile additional documents, if any. The search was not restricted to any of NSAIDs before prescribing for OA patient population [16–24]. publication language or status of the trial. Furthermore, the Oxaceprol (Anatomical Therapeutic.
Load more

Recommended publications
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,005,660 B2 Tygesen Et Al
    USOO9005660B2 (12) United States Patent (10) Patent No.: US 9,005,660 B2 Tygesen et al. (45) Date of Patent: Apr. 14, 2015 (54) IMMEDIATE RELEASE COMPOSITION 4,873,080 A 10, 1989 Bricklet al. RESISTANT TO ABUSEBY INTAKE OF 4,892,742 A 1, 1990 Shah 4,898,733. A 2f1990 DePrince et al. ALCOHOL 5,019,396 A 5/1991 Ayer et al. 5,068,112 A 11/1991 Samejima et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 5,082,655 A 1/1992 Snipes et al. Jan Martin Oevergaard, Frederikssund 5,102,668 A 4, 1992 Eichel et al. 5,213,808 A 5/1993 Bar Shalom et al. (DK); Joakim Oestman, Lomma (SE) 5,266,331 A 11/1993 Oshlack et al. 5,281,420 A 1/1994 Kelmet al. (73) Assignee: Egalet Ltd., London (GB) 5,352.455 A 10, 1994 Robertson 5,411,745 A 5/1995 Oshlack et al. (*) Notice: Subject to any disclaimer, the term of this 5,419,917 A 5/1995 Chen et al. patent is extended or adjusted under 35 5,422,123 A 6/1995 Conte et al. U.S.C. 154(b) by 473 days. 5,460,826 A 10, 1995 Merrill et al. 5,478,577 A 12/1995 Sackler et al. 5,508,042 A 4/1996 OShlack et al. (21) Appl. No.: 12/701.248 5,520,931 A 5/1996 Persson et al. 5,529,787 A 6/1996 Merrill et al. (22) Filed: Feb. 5, 2010 5,549,912 A 8, 1996 OShlack et al.
    [Show full text]
  • Oxaceprol Monotherapy Versus Oxaceprol and Glucosamine Combination Therapy for Knee Osteoarthritis
    Original Article ISSN (Print) : 2454-8952 International Journal of Medical and Dental Sciences, Vol 9(2), DOI: 10.18311/ijmds/2020/24871, July 2020 ISSN (Online) : 2320-1118 Oxaceprol Monotherapy versus Oxaceprol and Glucosamine Combination Therapy for Knee Osteoarthritis Vijay Kumar1, Sanjeev Sareen2, Shrey Bhatia3* 1Professor and Head, Department of Pharmacology, Government Medical College, Patiala – 147001, Punjab, India 2Associate Professor, Department of Orthopaedics, Government Medical College, Patiala – 147001, Punjab, India 3Junior Resident, Department of Pharmacology, Government Medical College, Patiala – 147001, Punjab, India; [email protected] Abstract Introduction: Osteoarthritis (OA) is the commonest form of arthritis which presents with joint pain and functional limitations. Oxaceprol, a derivative of hydroxyproline, inhibits leukocyte migration into the joints thus inhibiting Proline in chondrocytes. Aims and Objective: Glucosamineinflammatory combination process. Oxaceprol therapy also in patients increases diagnosed availability with of Knee Glucosamine Osteoarthritis and improving (KOA). Materials uptake ofand Glucosamine Methods: Thisand To demonstrate efficacy of Oxaceprol Monotherapy versus Oxaceprol and randomly received either Oxaceprol 600mg OD for 4 weeks, or combination of Oxaceprol 600mg OD and Glucosamine was an open labelled, parallel group, Randomized Controlled Trial where 40 adults age ≥50 years diagnosed with KOA visual analogue scale (VAS) recording from baseline to 4 weeks of treatment. Results: Our study showed that both Oxaceprol monotherapySulphate 1500mg (group OD A, for n=20), 4 weeks. and GlucosamineThe patients pluswere Oxaceprol analysed ascombination per the differences therapy (group between B, n=20) WOMAC improved scale scores, joint pain, and stiffness, and functionality as shown by analysing WOMAC scores before, and after 4 weeks of treatment.
    [Show full text]
  • La. ADMINISTRATION of DAMAN & DIU OFFICE of the HEAD of OFFICE/HEALTH OFFICER GOVERNMENT HOSPITAL, DIU (362 520)
    iiv utsr T;3Tvr V ifta UTrTT Farf% T 3r d (Z9't 3r-4c Tom) WT 4114C414, i TWt 3TF9c1I i, i la-362520. ir. ii3r41/ii T/1(2)/1 -20/2016-2017/301. fka* :- 02/08/2016. *-fr Wr3W) SMi T i ' i 'i11 * AT * ialft r Citct']^1 q T-^r&T (iriq+rf1 379ciis), ,1"d q, F71Ftq * , , U)' UM 79 M-401 3rt9'Trci, t a 4 111AIREF, Tc 'lr1 Lrd *U u hC iit rl *t 3TiV i f^lv ft &M WiiW W04cii3T1icn1b cr $1cci1/3rrqpV^ft34 i1 http_//daman.nprocure.com qi 3i- T fWf T 3Trr 9 I f1T 7W www. daman.nic.in qi 3ft < 6 t I WA i41j1f4 #f WT fur 3T ;5r7 T Tft (ftwfg fir N1i Ic i * Tr ) (3i,i1 ) 2. 3. 4. 01. iii T1Zp Fszi Er11 r Lrcr iri^rtl T. 4,50,000/- T. 2,000/- 3rF^-T1 cam, i a ' fv "'A iii V r c iff *+ is1$d 3T1- T T 1 f t ZR 4,A 3i3 c S WE# *t 3rfc r M ft :- 23/08/2016 41 12.00 Wi1 ^W. 3 i r a - l T 3 1 f r i tc I .,i V 9 1 t *r 3i1 err :- 23/08/2016 ;E^t 13.00 a4 -TW. Ar r ft 3ird-c i:T i)W# *t itrr :- 1 mm T3Tr t 23/ 08/2016 ;E^t 16.00 W4. f l ih1 -sir ift cr if s u1Tq 4 www.nprocure.com W{ 3rfc'IJR arilzrr T iRm i vf^ff v i i t m e1Jrr I vi^w ft ftDqpj AiTq i f! S # 1 fPjf^r # Fi Ti Tf f f + Tr i TVIU I f'df i S r &A.
    [Show full text]
  • Diclofenac in the Treatment of Pain in Patients with Rheumatic Diseases
    Review paper Reumatologia 2018; 56, 3: 174–183 DOI: https://doi.org/10.5114/reum.2018.76816 Diclofenac in the treatment of pain in patients with rheumatic diseases Justyna Kołodziejska, Michał Kołodziejczyk Department of Pharmaceutical Technology, Chair of Applied Pharmacy, Medical University of Lodz, Poland Abstract Diclofenac, a phenylacetic acid derivative, is a drug demonstrating high efficacy after oral adminis- tration in the treatment of pain and physical disability in rheumatic diseases. In view of the adverse effects associated with using diclofenac, it is necessary to consider all known drug safety informa- tion before the drug is selected for therapy and the dosage regimen is set for individual patients. Selecting an oral dosage form with specific properties determined by excipients is a method to im- prove the availability of the drug substance and, at the same time, minimize adverse drug reactions. An alternative to tablet or capsule dosage forms is diclofenac application to the skin. The proven efficacy of this method is further improved through the use of transdermal penetration enhancers and vehicle ingredients which provide dosage forms with specific physical properties. Key words: diclofenac, efficacy, adverse effects, dosage form technology. Introduction on the market also exhibit technological differences (dosage form modifications). Intense pharmacological Diseases of the musculo-skeletal system affect 70% and formulation research is currently being conducted of the population over the age of 50 years. Pain caused to obtain more effective and safer products [2]. by rheumatic diseases decreases or resolves during re- NSAIDs are effective in multiple indications. In rheu- mission-inducing treatment. Drugs used in the therapy matology, they are used in the treatment of a range of of rheumatic diseases usually have a late onset of ac- diseases including rheumatoid arthritis, lupus erythe- tion.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Attachment 9.Pdf
    Kyowa Hakko U.S.A., Inc. Dated: February 14, 2003 N-Acetyl-L-Hydroxyproline New Dietary Ingredient Notification Reference No. 9 ? Clin Rheumatol (2000) 19:99-104 0 2000 Clinical Rheulnatology Clinical Rheumatology Original Article Oxaceprol is a Well-Tolerated Therapy for Osteoarthritis with Efficacy Equivalent to Diclofenac G. Herrmann’, D. Steeger’, M. Klasser*, J. Wirbitzky’, M. Fiirst4, R. Venbrocks’, H. Rohde6, D. Jungmiche17, H. D. Hildebrandt’, M. J. Parnham9, W. Gimbell’ and H. Dirschedl’ ‘BayerischesRotes Kreuz, Orthop&discheKlinik Lindenlohe,Schwandorf; ‘Gesellschaft fur wissenschaftlicheDatenverarbeitung + Didaktik mbH, MiihlheimiMain; 3Kurpark-Klinik,Bad Schussenried;4Schlo13park-Kliniken, Bad Waldsee;‘ Orthopgdische Uniklinik am Rudolf-Elle-Krankenhaus,Eisenberg; 6Fachklinikfiir Orthopadieund Rheumatologie,Oberstdorf; 7Fachklinik fir Orthopadie,Bad Dfiben; ‘Klinik am Homberg,Bad Wildungen;“ PamhamAdvisory Services,Bonn; and “ChephasaarGmbH, St Ingbert, Germany Abstract: The therapeutic equivalence and safety of was statistically significant (p = 0.04106) for the number treatment for 21 days with 400 mg t.i.d. oxaceprol (n = of these adverse events. Oxaceprol is therapeutically 132) and 50 mg t.i.d. diclofenac (n = 131) were assessed equivalent to diclofenac, but better tolerated than in a multicentre, randomised, double-blind study of a diclofenac in the treatment of osteoarthritis. mixed population of patients with osteoarthritis of the knee and/or hip. In a per-protocol analysis of efficacy, Keywords: Diclofenac; Lequesne index; Osteoarthritis; the mean Lequesne index decreasedby 2.5 points in the Oxaceprol; Pain oxaceprol group (n = 109) and by 2.8 points in the diclofenac group (n = 109). The 95% confidence interval for the end-point difference revealed therapeutic equivalence. This was confirmed by assessments (visual analogue scale) of pain at rest, weight-bearing pain, pain on standing and pain on movement, all of Introduction which decreased to a similar extent under both treatments.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl Et Al
    US 2005O249806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl et al. (43) Pub. Date: Nov. 10, 2005 (54) COMBINATION OF PROTON PUMP Related U.S. Application Data INHIBITOR, BUFFERING AGENT, AND NONSTEROIDAL ANTI-NFLAMMATORY (60) Provisional application No. 60/543,636, filed on Feb. DRUG 10, 2004. (75) Inventors: Gerald T. Proehl, San Diego, CA (US); Publication Classification Kay Olmstead, San Diego, CA (US); Warren Hall, Del Mar, CA (US) (51) Int. Cl." ....................... A61K 9/48; A61K 31/4439; A61K 9/20 Correspondence Address: (52) U.S. Cl. ............................................ 424/464; 514/338 WILSON SONS IN GOODRICH & ROSAT (57) ABSTRACT 650 PAGE MILL ROAD Pharmaceutical compositions comprising a proton pump PALO ALTO, CA 94304-1050 (US) inhibitor, one or more buffering agent and a nonsteroidal ASSignee: Santarus, Inc. anti-inflammatory drug are described. Methods are (73) described for treating gastric acid related disorders and Appl. No.: 11/051,260 treating inflammatory disorders, using pharmaceutical com (21) positions comprising a proton pump inhibitor, a buffering (22) Filed: Feb. 4, 2005 agent, and a nonsteroidal anti-inflammatory drug. US 2005/0249806 A1 Nov. 10, 2005 COMBINATION OF PROTON PUMP INHIBITOR, of the Stomach by raising the Stomach pH. See, e.g., U.S. BUFFERING AGENT, AND NONSTEROIDAL Pat. Nos. 5,840,737; 6,489,346; and 6,645,998. ANTI-NFLAMMATORY DRUG 0007 Proton pump inhibitors are typically prescribed for Short-term treatment of active duodenal ulcers, gastrointes CROSS REFERENCE TO RELATED tinal ulcers, gastroesophageal reflux disease (GERD), Severe APPLICATIONS erosive esophagitis, poorly responsive Symptomatic GERD, 0001.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group M01 (Antiinflammatory and antirheumatic products) Table of Contents Page INTRODUCTION 6 DISCLAIMER 8 GLOSSARY OF TERMS USED IN THIS DOCUMENT 9 ACTIVE SUBSTANCES Phenylbutazone (ATC: M01AA01) 11 Mofebutazone (ATC: M01AA02) 17 Oxyphenbutazone (ATC: M01AA03) 18 Clofezone (ATC: M01AA05) 19 Kebuzone (ATC: M01AA06) 20 Indometacin (ATC: M01AB01) 21 Sulindac (ATC: M01AB02) 25 Tolmetin (ATC: M01AB03) 30 Zomepirac (ATC: M01AB04) 33 Diclofenac (ATC: M01AB05) 34 Alclofenac (ATC: M01AB06) 39 Bumadizone (ATC: M01AB07) 40 Etodolac (ATC: M01AB08) 41 Lonazolac (ATC: M01AB09) 45 Fentiazac (ATC: M01AB10) 46 Acemetacin (ATC: M01AB11) 48 Difenpiramide (ATC: M01AB12) 53 Oxametacin (ATC: M01AB13) 54 Proglumetacin (ATC: M01AB14) 55 Ketorolac (ATC: M01AB15) 57 Aceclofenac (ATC: M01AB16) 63 Bufexamac (ATC: M01AB17) 67 2 Indometacin, Combinations (ATC: M01AB51) 68 Diclofenac, Combinations (ATC: M01AB55) 69 Piroxicam (ATC: M01AC01) 73 Tenoxicam (ATC: M01AC02) 77 Droxicam (ATC: M01AC04) 82 Lornoxicam (ATC: M01AC05) 83 Meloxicam (ATC: M01AC06) 87 Meloxicam, Combinations (ATC: M01AC56) 91 Ibuprofen (ATC: M01AE01) 92 Naproxen (ATC: M01AE02) 98 Ketoprofen (ATC: M01AE03) 104 Fenoprofen (ATC: M01AE04) 109 Fenbufen (ATC: M01AE05) 112 Benoxaprofen (ATC: M01AE06) 113 Suprofen (ATC: M01AE07) 114 Pirprofen (ATC: M01AE08) 115 Flurbiprofen (ATC: M01AE09) 116 Indoprofen (ATC: M01AE10) 120 Tiaprofenic Acid (ATC:
    [Show full text]
  • Obesity Invites Osteo-Arthritis in Young Women Weight Reduction Be the Main Stay of Management! a Case Study
    5 ISSN: 2687-816X DOI: 10.33552/GJOR.2021.03.000565 Global Journal of Orthopedics Research Research Article Copyright © All rights are reserved by S Tejesh Obesity Invites Osteo-Arthritis in Young Women Weight Reduction be the Main Stay of Management! A Case Study S Tejesh1* and Suresh Kishanrao2 1 S Tejesh MPH, School of Public Health & Environmental Sciences, Karnataka state rural development and panchayat raj university Gadag, India 2 Suresh Kishanrao, Public Health Consultant and Vissiting Professor, MPH, School of Public Health & Environmental Sciences, KSRDPRU, Gadag, India *Corresponding author: S Tejesh, MPH, School of Public Health & Environmental Received Date: July 26, 2021 Sciences, Karnataka state rural development and panchayat raj university Gadag, India. Published Date: August 18, 2021 Abstract Knee osteoarthritis (OA), also known as degenerative joint disease of the knee, is typically the result of wear and tear and progressive loss of articular cartilage. Age, weight and gender are the predisposing risk factors and symptoms are swelling, pain and stiffness at knee joint. We here present a case of 43-year-old housewife reported with pain, swelling and stiffness at right knee on 5 May 2021 was taken to nearby orthopedician. After physical examination and radiological investigation, she was diagnosed with knee osteoarthritis. He treated her with some analgesics and anti-inflammatory drugs and suggested to take physical therapy and counselled for weight reduction. In a follow up visit she had reduced her weight byBackground 3 kgs in a month’s time and was doing fine. We infer that weight of an individual plays an important role in the incidence of knee osteoarthritis.
    [Show full text]